{"entity":{"id":"nct07391566","kind":"trial","name":"LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","aka":[],"tldr":"A phase 1/2 trial of bevacizumab (glioblastoma use) and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Luye Pharma Group Ltd., not yet recruiting.","summary":"LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation is a phase 1/2, interventional study registered as NCT07391566 by Luye Pharma Group Ltd., with a registry enrolment figure of 99 participants, started 2026-03-31 and due to reach its primary completion in 2028-12-31. Interventions recorded: LPM6690176; Bevacizumab; FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan). Conditions listed: Metastatic Colorectal Cancer (mCRC). Primary outcome: Phase Ib: Dose-limiting toxicities (DLTs); Phase Ib: Maximum tolerated dose (MTD); Phase 1b: Recommended Phase 2 Dose (RP2D). Colorectal eligibility wording from the registry: \"Histologically confirmed metastatic colorectal cancer (CRC) with RAS mutation;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07391566","url":"https://clinicaltrials.gov/study/NCT07391566"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["bevacizumab-glioma","folfiri"],"companies":["luye-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07391566","phase":"1/2","setting":"Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of LPM6690176 Capsules in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","sponsor":"Luye Pharma Group Ltd.","enrolled":99,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07391566/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"}],"company":[{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","route":"/companies/luye-pharma/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}